Stock LXEO LEXEO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Lexeo Therapeutics, Inc.

Equities

LXEO

US52886X1072

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-15 pm EDT 		5-day change 1st Jan Change
13.96 USD -0.07% Intraday chart for Lexeo Therapeutics, Inc. +1.75% +4.02%
May. 09 Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 01 Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug
MT
Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy
MT
Lexeo Therapeutics, Inc. Announces the U.S. Food and Drug Administration Grants Fast Track Designation for LX2006, an Aav-Based Gene Therapy Candidate for the Treatment of Friedreich?s Ataxia Cardiomyopathy
CI
Lexeo Therapeutics' Q4 Net Loss Narrows; Cash Runway Extended to 2027 -- Shares Jump Pre-Bell
MT
LEXEO: ENTERED INTO COMMON STOCK PURCHASE AGREEMENT TO…
RE
Lexeo Therapeutics, Inc. has completed an IPO in the amount of $100.00001 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LXEO Stock
  4. News Lexeo Therapeutics, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW